Enrolling by Invitation
A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
NCT06755515
- Conditions
- Cervical Cancer, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, +11 more
- Locations
-
- Shandong New Time Pharmaceutical Co., LTD Linyi, Shandong, China